Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT
exam within the past year will be included. Subjects will be treated with calcitonin to lower
calcium levels immediately prior to reimaging. The goal of this study is to determine whether
lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of
SPECT-CT to localize parathyroid adenoma.